Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

X0202 SCHEDULE 13D/A 0001841619 XXXXXXXX LIVE 6 Common Stock 08/31/2026 false 0001787740 918942202 Valion Bio, Inc. 1305 E. Houston Street, Building 1 Suite 311 San Antonio TX 78205 Maier J. Tarlow (646) 845-0040 2 Wooster Street, 2nd Floor NEW YORK NY 10013 0001841619 N 3i, LP a WC N DE 0.00 133005.00 0.00 133005.00 133005.00 N 9.9 PN As more fully described in Item 5 of this Amendment No. 6 (as defined in Item 1 below), such shares and percentage are based on 1,285,626 shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") outstanding as of August 24, 2026, as verified with the Issuer. Beneficial ownership consists of 87,248 shares of Common Stock directly held by 3i, LP and 45,757 shares of Common Stock issuable in any combination upon (i) exercises of certain common stock purchase warrants (the "Warrants") held directly by 3i, LP, which exercises are subject to a 9.99% beneficial ownership limitation provision (a "Blocker"), (ii) conversions of a senior secured convertible note in the original principal amount of $16,253,147.10 (the "Note") held directly by 3i, LP, which conversions are subject to a Blocker, (iii) conversions of shares of Series B Convertible Preferred Stock, par value $0.0001 per share, of the Issuer (the "Series B Preferred Stock") directly held by 3i, LP, which conversions are subject to a Blocker, and (iv) conversions of shares of Series C Convertible Preferred Stock, par value $0.0001 per share, of the Issuer (the "Series C Preferred Stock") directly held by the 3i, LP, which conversions are subject to a Blocker. Unless the context expressly dictates otherwise, all references to share and per share amounts in this Amendment No. 6 give effect to the Issuer's 1-for-25 reverse stock split effected at 12:01 a.m. Eastern Time on August 31, 2026. Y Tumim Stone Capital, LLC a WC N DE 0.00 0.00 0.00 0.00 0.00 N 0.00 OO Y 3i Management LLC a WC N DE 0.00 133005.00 0.00 133005.00 133005.00 N 9.9 OO As more fully described in Item 5 of this Amendment No. 6, such shares and percentage are based on 1,285,626 shares of Common Stock outstanding as of August 24, 2026, as verified with the Issuer. Beneficial ownership consists of 87,248 shares of Common Stock indirectly held by the reporting person and 45,757 shares of Common Stock issuable in any combination upon (i) exercises of the Warrants indirectly held by the reporting person, which exercises are in each case subject to a Blocker, and (ii) conversions of the Note, shares of Series B Preferred Stock and shares of Series C Preferred Stock indirectly held by the reporting person, which conversions are in each case subject to a Blocker. Y Maier J. Tarlow a WC N X1 0.00 133005.00 0.00 133005.00 133005.00 N 9.9 IN As more fully described in Item 5 of this Amendment No. 6, such shares and percentage are based on 1,285,626 shares of Common Stock outstanding as of August 24, 2026, as verified with the Issuer. Beneficial ownership consists of 87,248 shares of Common Stock indirectly held by the reporting person and 45,757 shares of Common Stock issuable in any combination upon (i) exercises of the Warrants indirectly held by the reporting person, which exercises are in each case subject to a Blocker, and (ii) conversions of the Note, shares of Series B Preferred Stock and shares of Series C Preferred Stock indirectly held by the reporting person, which conversions are in each case subject to a Blocker. Common Stock Valion Bio, Inc. 1305 E. Houston Street, Building 1 Suite 311 San Antonio TX 78205 This Amendment No. 6 to Schedule 13D (this "Amendment No. 6") relates to the common stock, par value $0.0001 per share (the "Common Stock") of Valion Bio, Inc., a Delaware corporation (the "Issuer"), and amends the Schedule 13D filed on August 3, 2026, as amended by Amendment No. 1 filed on August 11, 2026, Amendment No. 2 filed on August 14, 2026, Amendment No. 3 filed on August 19, 2026, Amendment No. 4 filed on August 24, 2026 and Amendment No. 5 filed on August 27, 2026 (as amended, the "Original Schedule 13D") by (a) 3i, LP, (b) Tumim Stone Capital, LLC ("Tumim Stone"), (c) 3i Management LLC ("3i Management") and (d) Maier J. Tarlow ("Mr. Tarlow" and, together with 3i, LP, 3i Management and Tumim Stone, the "Reporting Persons") as set forth herein. This Item 2(a) is not being amended by this Amendment No. 6. This Item 2(b) is not being amended by this Amendment No. 6. This Item 2(c) is not being amended by this Amendment No. 6. This Item 2(d) is not being amended by this Amendment No. 6. This Item 2(e) is not being amended by this Amendment No. 6. This Item 2(f) is not being amended by this Amendment No. 6. This Item 3 is not being amended by this Amendment No. 6. Item 4 of the Original Schedule 13D is hereby amended to add the following paragraph at the end thereof: On August 31, 2026, the Issuer and 3i, LP entered into a letter agreement, pursuant to which the Issuer issued to 3i, LP (a) 100 shares of Series B Preferred Stock, (b) Warrants to purchase 3,077 shares of Common Stock at an initial exercise price of $3.62 per share, (c) 7,637 shares of Series C Preferred Stock and (d) Warrants to purchase 1,053,969 shares of Common Stock for an initial exercise price of $3.62 per share, for an aggregate purchase price of $7,737,000, consisted of (a) $6,137,000 retained by 3i, LP to satisfy overdue cash true-up payments pursuant to Section 6(b) of the Certificate of Designation of Rights and Preferences of the Series C Preferred Stock, (b) $100,000 retained by 3i, LP to pay the fees of its legal counsel in connection with the purchase of the Issuer's securities by it and (c) $1,500,000 paid to the Issuer in immediately available funds. Item 5(a) of the Original Schedule 13D is hereby amended and restated as follows: See rows (11) and (13) of the cover pages to this statement for the aggregate number of shares of Common Stock and percentages of the shares of Common Stock beneficially owned by each of the Reporting Persons. The shares and percentages are based on 1,285,626 shares of Common Stock outstanding as of August 24, 2026, as verified with the Issuer. This Item 5(b) is not being amended by this Amendment No. 6. This Item 5(c) is hereby amended to add the transactions set forth in Exhibit 10 attached herein. This Item 5(d) is not being amended by this Amendment No. 6. This Item 5(e) is not being amended by this Amendment No. 6. This Item 6 is not being amended by this Amendment No. 6. Item 7 of the Original Schedule 13D is hereby amended to add the following exhibits: Exhibit 10: Additional Transactions Exhibit 11: Letter Agreement between the Issuer and 3i, LP, dated August 31, 2026 (incorporated by reference to Exhibit 10.1 to the Issuer's Current Report on Form 8-K filed on September 1, 2026) 3i, LP /s/ Maier J. Tarlow Maier J. Tarlow, manager of 3i Management LLC, general partner of 3i, LP 09/02/2026 Tumim Stone Capital, LLC /s/ Maier J. Tarlow Maier J. Tarlow, manager of 3i Management LLC, manager of Tumim Stone Capital, LLC 09/02/2026 3i Management LLC /s/ Maier J. Tarlow Maier J. Tarlow, Manager 09/02/2026 Maier J. Tarlow /s/ Maier J. Tarlow Maier J. Tarlow 09/02/2026